Phase 4 N=74 Randomized Single-blind Treatment

Liposomal Bupivacaine Versus Lidocaine for Skin Graft Donor Site Pain

Pain, Postoperative · Burns

Bottom Line

View on ClinicalTrials.gov: NCT03854344 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Mar 2026

Primary outcome: Primary: A Measurement of Post Operative Pain Involving Skin Graft Donor Site Using Visual Analog Scale (VAS) Ranging 0-10, at 8 Hours Post-operatively — 3.14; 3.68; 3.67 score on a scale 0-10

Study Design & Population

Study type: Interventional
Phase: Phase 4
Interventions: Lidocaine Hydrochloride (Drug); Liposomal bupivacaine (Drug); Bupivacaine Hydrochloride (Drug)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: University of Kansas Medical Center
Primary completion: Aug 2025

Outcome Measures

Outcome	Result	p-value
PRIMARY A Measurement of Post Operative Pain Involving Skin Graft Donor Site Using Visual Analog Scale (VAS) Ranging 0-10, at 8 Hours Post-operatively	3.14; 3.68; 3.67	—
SECONDARY Opioid Pain Medication Consumption up to 72 Hours Post-operatively Will be Compared Between the Subjects Who Are Given Liposomal Bupivacaine (Exparel) and Lidocaine at the Donor Sites	36.21; 49.91; 44.59	—
SECONDARY Pain Scores Over 72 Hours After Surgery	4.88; 3.64; 3	—

Summary

Donor site pain study comparing post-operative donor site pain and opioid consumption after use of Lidocaine, Liposomal Bupivicaine or regional nerve block for split thickness skin graft harvesting in patients with less than 20% TBSA burn wounds and less than %5 Deep partial or full thickness burn wounds.

Eligibility Criteria

Inclusion Criteria

Spanish/English speaking
20% TBSA burn injury; > 5% TBSA deep partial or full thickness burn
pregnant
allergy to lidocaine or other local anesthetics
burns to anterior thighs

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03854344). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.